Global Regulatory Footprint Medis provides in-house development and regulatory support to secure marketing authorizations across a broad international landscape, supported by Teva capabilities, making it an attractive partner for license deals across markets and near patent expiries.

Oncology Focus Expansion The portfolio includes a growing range of specialist oncology products and formulations, enabling potential collaborations for licensing or co development of oncology generics and related solid dose therapies.

Teva Backing With the support of Teva’s development and manufacturing resources, Medis offers scale, robust quality controls, and secure handling of confidential information, facilitating large licensing agreements and reliable supply chains.

Trusted Partnerships A long-tenured client base and established relationships reflect reliability and loyalty, suggesting Medis is well suited for long-term licensing partnerships and ongoing distribution arrangements.

Broad Portfolio A sizeable catalog of generic products across tablets, capsules, and injections provides multiple entry points for licensing opportunities across therapeutic areas and geographies, including oncology-focused offerings.